Trial · NCT02162420
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
NCT02162420, Not applicable, Completed, Masonic Cancer Center, University of Minnesota; results first posted 2025-05-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia. Trials, record NCT02162420. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02162420
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
- NCT number
- NCT02162420
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 61 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Dyskeratosis Congenita, Aplastic Anemia
- Interventions
- Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, Anti-thymocyte globulin
- First posted
- 2014-06-12
- Last updated
- 2025-05-08
- Results first posted
- 2025-05-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Neutrophil Engraftment | Day 42 | Incidence of neutrophil engraftment by day 42. |
| Primary | Incidence of Platelet Engraftment | 1 year | Incidence of platelet engraftment at 1 year |
| Secondary | Incidence of Regimen Related Mortality | Day 100 | Incidence of regimen related mortality by day 100. |
| Secondary | Incidence of Acute Graft-versus-host Disease | Day 100 | Incidence of acute graft-versus-host disease by day 100. |
| Secondary | Incidence of Chronic Graft-versus-host Disease | 6 Months | Incidence of chronic graft-versus-host disease by 6 months |
| Secondary | Incidence of Chronic Graft-versus-host Disease | 1 Year | Incidence of chronic graft-versus-host disease by 1 year |
| Secondary | Incidence of Secondary Malignancies | 1 Year | Incidence of secondary malingancies |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Neutrophil Engraftment | Day 42 | Percentage of participants | NUMBER | |
| PRIMARY | Incidence of Platelet Engraftment | 1 year | Percentage of participants | NUMBER | |
| SECONDARY | Incidence of Regimen Related Mortality | Day 100 | Percentage of participants | NUMBER | |
| SECONDARY | Incidence of Acute Graft-versus-host Disease | Day 100 | Percentage of participants | NUMBER | |
| SECONDARY | Incidence of Chronic Graft-versus-host Disease | 6 Months | Percentage of participants | NUMBER | |
| SECONDARY | Incidence of Chronic Graft-versus-host Disease | 1 Year | Percentage of participants | NUMBER | |
| SECONDARY | Incidence of Secondary Malignancies | 1 Year | Percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Neutrophil Engraftment | Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor | 100 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Incidence of Neutrophil Engraftment | Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor | 100 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Incidence of Neutrophil Engraftment | Arm C: Severe Aplastic Anemia, Matched Related Donor | 96 | 95% Confidence Interval 82 to 100 | Percentage of participants | |
| Incidence of Neutrophil Engraftment | Arm E: Severe Aplastic Anemia, PTCy Platform | 100 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Incidence of Platelet Engraftment | Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor | 100 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Incidence of Platelet Engraftment | Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor | 100 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Incidence of Platelet Engraftment | Arm C: Severe Aplastic Anemia, Matched Related Donor | 96 | 95% Confidence Interval 82 to 100 | Percentage of participants | |
| Incidence of Platelet Engraftment | Arm E: Severe Aplastic Anemia, Haploidentical Donor | 100 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Incidence of Regimen Related Mortality | Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor | 0 | 95% Confidence Interval 0 to 0 | Percentage of participants | |
| Incidence of Regimen Related Mortality | Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor | 6 | 95% Confidence Interval 1 to 33 | Percentage of participants |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 results by groupParticipant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor | 12 | |
| Overall Study | STARTED | Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor | 18 | |
| Overall Study | STARTED | Arm C: Severe Aplastic Anemia, Matched Related Donor | 23 | |
| Overall Study | STARTED | Arm D: Dyskeratosis Congenita, PTCy Platform | 0 | |
| Overall Study | STARTED | Arm E: Severe Aplastic Anemia, PTCy Platform | 8 | |
| Overall Study | COMPLETED | Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor | 11 | |
| Overall Study | COMPLETED | Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor | 15 | |
| Overall Study | COMPLETED | Arm C: Severe Aplastic Anemia, Matched Related Donor | 22 | |
| Overall Study | COMPLETED | Arm D: Dyskeratosis Congenita, PTCy Platform | 0 | |
| Overall Study | COMPLETED | Arm E: Severe Aplastic Anemia, PTCy Platform | 8 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor | 1 | 12 |
| Total, all-cause mortality | Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor | 3 | 18 |
| Total, all-cause mortality | Arm C: Severe Aplastic Anemia, Matched Related Donor | 1 | 23 |
| Total, all-cause mortality | Arm D: Dyskeratosis Congenita, PTCy Platform | 0 | 0 |
| Total, all-cause mortality | Arm E: Severe Aplastic Anemia, PTCy Platform | 0 | 8 |
| Total, other adverse events | Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor | 0 | 12 |
| Total, other adverse events | Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor | 0 | 18 |
| Total, other adverse events | Arm C: Severe Aplastic Anemia, Matched Related Donor | 0 | 23 |
| Total, other adverse events | Arm D: Dyskeratosis Congenita, PTCy Platform | 0 | 0 |
| Total, other adverse events | Arm E: Severe Aplastic Anemia, PTCy Platform | 0 | 8 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02162420
GET https://conductscience.org/api/trials/v1/NCT02162420/results?page=2